Crossmark

Epidemiology and in vitro activity of ceftazidime–avibactam, meropenem–vaborbactam, imipenem–relebactam, eravacycline, plazomicin, and comparators against Greek carbapenemase-producing Klebsiella pneumoniae isolates

Crossref DOI link: https://doi.org/10.1007/s15010-021-01735-1

Published Online: 2021-12-02

Published Print: 2022-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Maraki, Sofia http://orcid.org/0000-0003-0945-1732
Mavromanolaki, Viktoria Eirini

Magkafouraki, Eleni

Moraitis, Panagiotis

Stafylaki, Dimitra

Kasimati, Anna

Scoulica, Effie
License Information

Text and Data Mining valid from 2021-12-02

Version of Record valid from 2021-12-02
More Information

Article History

Received: 14 October 2021

Accepted: 20 November 2021

First Online: 2 December 2021

Change Date: 6 October 2022

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s15010-022-01918-4

Declarations

:

: The authors have no relevant financial or non-financial interests to disclose.

: This study was approved by the Ethical Committee of the University Hospital of Heraklion and met the guidelines of Helsinki declarations.

: Not applicable.

Updates are available Correction dated 2022-10-06

Click to view Correction: https://doi.org/10.1007/s15010-022-01918-4